Previous 10 | Next 10 |
IND Application filed for potential best-in-class ADC, VIP943; Phase 1 trial expected to begin Q4 2023 Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class SMDC Cash balance expected to support planned operations into late 2024 PALO ALTO, Cali...
2023-07-26 12:59:58 ET Gainers: Vicor Corporation ( VICR ) +51% . Tupperware Brands Corporation ( TUP ) +43% . ABVC BioPharma ( ABVC ) +39% . Armata Pharmaceuticals ( ARMP ) +30% . PacWest Bancorp ( PACW ) +27% . XPeng ( XP...
2023-05-12 07:36:39 ET Vincerx Pharma press release ( NASDAQ: VINC ): Q1 GAAP EPS of -$0.68 misses by $0.03 . Vincerx had approximately $39.8 million in cash, cash equivalents and marketable securities as of March 31, 2023, as compared to approximately $52.5 million as...
Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class α v β 3 small molecule drug conjugate (SMDC) for the treatment of solid tumors IND filing for VIP943, a next-generation antibody-drug conjugate (ADC), for treatment o...
2023-04-26 10:09:11 ET Gainers: Scilex Holding ( SCLX ) +14% . Cytek Biosciences ( CTKB ) +12% . Minerva Neurosciences ( NERV ) +10% . Vincerx Pharma ( VINC ) +9% . LianBio ( LIAN ) +7% . Losers: ZyVersa Therapeutics ( Z...
PALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of VIP924 preclinical data at the 2023 A...
PALO ALTO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of preclinical data on novel integrin ...
PALO ALTO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of preclinical data of VIP236 monotherap...
2023-03-28 17:10:38 ET Vincerx Pharma press release ( NASDAQ: VINC ): Q4 GAAP EPS of -$0.65 misses by $0.04 . Vincerx had $52.5 million in cash, cash equivalents and marketable securities as of December 31, 2022, as compared to $111.5 million as of December 31, 2021. B...
First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an α v β 3 small molecule drug conjugate (SMDC) in advanced solid tumors IND filing for antibody drug conjugate (ADC) VIP943 remains on track for mid-2023; expected to be ...
News, Short Squeeze, Breakout and More Instantly...
Vincera Pharma Inc Com Company Name:
VINC Stock Symbol:
NASDAQ Market:
Vincera Pharma Inc Com Website:
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health (NIH) and Vincerx announced positive result...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock,...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warra...